Published online 2015 July 22.

# Efficacy of Hepatoprotective Agents With or Without Antiviral Drugs on Liver Function and Fibrosis in Patients With Hepatitis B: A Meta-Analysis

Li-Hui Long<sup>1,\*</sup>; Cai-Qin Xue<sup>1</sup>; Jun-Feng Shi<sup>1</sup>; Juan-Ni Dong<sup>1</sup>; Li Wang<sup>2</sup>

<sup>1</sup>Department of Pharmacy, the First Affiliated Hospital of Xi'an Medical College, Xi'an, Shaanxi 710077, China <sup>2</sup>Research Division, the First Affiliated Hospital of Xi'an Medical College, Xi'an, Shaanxi 710077, China

\*Corresponding Author: Li-Hui Long, Department of Pharmacy, the First Affiliated Hospital of Xi'an Medical College, Xi'an, Shaanxi 710077, China. Tel: +86-2984277599, Fax: +86-2984277599, E-mail: llhbjd@126.com

Received: April 11, 2015; Revised: May 17, 2015; Accepted: May 31, 2015

Context: To systematically evaluate the effects of hepatoprotective agents, when delivered either alone or in combination with other antiviral or non-antiviral drugs in patients with hepatitis B and hepatic fibrosis.

Objectives: The current randomized controlled clinical trials aimed to evaluate the efficacy of combinations of antiviral and non-antiviral hepatoprotective agents on indexes of liver function and liver fibrosis in patients with hepatitis B.

Data Sources: Published literatures in Chinese and English on hepatoprotective treatment strategies for chronic hepatitis B and liver fibrosis were searched in three databases and randomized controlled clinical trials were selected.

Study Selection: Data were extracted according to a variety of inclusion and exclusion criteria. Meta-analysis was employed to analyze the data.

Results: A total of 22 randomized controlled trials encompassing 1,714 cases were considered in the meta-analysis. The obtained results indicated that the combination of antiviral drug and hepatoprotective agent was better than antiviral drug alone to improve liver function. Similarly, regarding liver fibrosis, using two different hepatoprotective agents was better than using one agent. The normalization rates of Aminotransferase (ALT) and total Bilirubin (TBil) were improved 25.7% by two hepatoprotective agents compared to the single agent. Acetylcysteine was superior to ursodeoxycholic acid or silibinin to reduce ALT. Ursodeoxycholic acid was superior to acetylcysteine or silibinin to reduce TBIL.

Conclusions: Hepatoprotective agents combined with antiviral drugs can significantly improve liver function and liver fibrosis parameters in patients with hepatitis B.

Keywords: Hepatitis B; Liver Cirrhosis; Meta-Analysis; Ursodeoxycholic Acid (UDCA); Silibinin; Acetylcysteine

#### 1. Context

At present, Hepatitis B Virus (HBV) infection is an important public health problem worldwide. Hepatitis B can lead to serious liver diseases, including cirrhosis, liver cancer. In China, approximately 120 million people are infected with the Hepatitis B Virus (1). Alavian et al. reported that about 1 million people are infected with HBV in Iran, and 15% to 40% of the patients with hepatitis B may develop cirrhosis or liver cancer (2). Liver fibrosis is a healing response, but the excessive accumulation of extracellular matrix (ECM) components in the liver often leads to severe forms of liver fibrosis, and ultimately cirrhosis with liver dysfunction (3-5). Early cirrhosis may be reversible. Therefore, prompt diagnosis and intervention are critical in limiting disease progression (6). Clinically, the existing hepatoprotective agents include Ursodesoxycholic acid (UDCA), silibinin, and N-acetylcysteine (NAC).

UDCA is a hydrophilic bile acid, which alters the ratio of hydrophilic-to-hydrophobic components in the bile acid pool. It promotes the secretion of endogenous bile acids such as chenodeoxycholic and lithocholic acid, and improves cholestasis. UDCA is mainly used to treat primary biliary cirrhosis, hepatitis B associated liver fibrosis, and cholestatic liver disease, the efficacy is certain. Some studies reported that UDCA protects liver cell membrane and enhances immune function. These mechanisms may be related to the ability of ursodeoxycholic acid to regulate cell cycle, apoptosis and protein biosynthesis of liver cells. Alternatively, the increased pool of hydrophilic bile acid and the stability of the cell membrane may play an important protective role (7, 8). UDCA, which causes minimal damage and is non-toxic to liver cells, is an effective hepatoprotective agent and cholagogue (9). Results of long-term observational studies showed that ursodeoxycholic acid can significantly reduce the development of hepatic fibrosis (8, 10, 11).

Silibinin is derived from milk thistle, an important medicinal plant that is roots, leaves and seeds exert a variety of therapeutic effects, including hepatoprotective, antioxidant, and anti-lipogenic properties (12). In the United States and Europe, about 65% of patients with liver dis-

Copyright @ 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

ease use Chinese medical preparations which include milk thistle as their most common ingredient (13). Silymarin, a mixture of flavonoids and wood ester pigment compounds, is extracted from milk thistle seeds. Silymarin contains silibinin, silychristin, and silymarin Ning with a large amount of silibinin. it is noteworthy that, silibinin is the main active ingredient of silymarin (14). In recent years, silibinin has been used to treat liver cirrhosis, hepatitis, liver fibrosis and alcoholic liver disease (15).

N-acetylcysteine (NAC) is an intracellular glutathione precursor, which can enhance the activity of glutathione transferase and promote the detoxification of free radicals. nitric oxide (NO) and its metabolite can improve microcirculation, increase tissue oxygen, and enhance the repair of damaged tissue (16, 17). In recent years, clinical studies have demonstrated that NAC is not only effective to treat liver failure caused by excessive acetaminophen (paracetamol), but is also useful for liver disease arising from other causes (18). NAC reduces serum Total Bilirubin (TBil) and aminotransferases, and increases Prothrombin activity (PTA) in patients with severe chronic hepatitis B (19).

# 2. Objectives

The current study aimed to search randomized controlled clinical trials to evaluate the efficacy of antiviral and non-antiviral hepatoprotective agents combinations on the indexes of liver function and liver fibrosis in patients with hepatitis B.

# 3. Data Sources

Papers written in either English or Chinese describing the use of hepatoprotective agents to treat hepatitis and liver fibrosis were retrieved. Using "chronic hepatitis B, hepatitis B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin, silybin meglumine), acetylcysteine and ursodeoxycholic bile acid (UDCA)", the study retrieved papers indexed in the China national knowledge internet (CNKI) (2000 - 2012), Pubmed (19832013), Embase (2000 - 2013) and Cochrane databases (1992 - 2012).

# 4. Study Selection

# 4.1. Inclusion and Exclusion Criteria

# 4.1.1. Inclusion Criteria

Hepatitis B infection or liver fibrosis; chronic hepatitis B was diagnosed if HBV history or HBV markers were persistently positive for more than six months and serum alanine aminotransferase levels exceeded 80 IU/L, and hepatic fibrosis was estimated by indexes containing the following markers: HA, LN, C-IV, PIIIP (13). Results indicators including Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), TBIL, gamma-Glutamyl Transpeptidase ( $\gamma$ -GGT), Alkaline Phosphatase (ALP), Hyaluronic acid (HA), Laminin (LN), Collagen type IV (CIV), and Procollagen III peptide (PIIIP). Trials were limited to those comparing the efficacy of different drugs or placebo.

### 4.1.2. Exclusion Criteria

Studies in which non-protective liver drugs were used to treat viral hepatitis or liver fibrosis; animal experiments and reviewed papers that did not contain clinical data; pregnant and lactating female patients with liver disease. The therapy course was less than three weeks; liver biochemical markers were normal.

# 4.2. Outcome Indicators

Outcomes were reported in terms of efficacy as follows: 1) Markedly effective: patients underwent full recovery or exhibited significant improvements in their clinical symptoms; levels of ALT, AST, GGT, TBIL and other basic indicators of liver function were restored to within the normal range. 2) Effective: moderate improvement of clinical symptoms, signs and liver function. 3) Ineffective: no obvious improvement or exacerbation of symptoms, signs and liver function indexes.

# 4.3. Statistical Analysis

RevMan5.2 software was used to analyze the data. For classified data, risk ratio (RR) and 95% confidence interval (95% CI) were used. For continuous data, weighted mean difference (WMD) and 95% CI were used. If I2 < 50%, the test was considered uniform with no statistically significant heterogeneity, the fixed effects model was used if I2 > 50%, a random effects model was used. A Funnel plot was used to evaluate possible publication bias.

# 5. Data Extraction

Two authors discussed all data sets before extracting them from the published literature. To avoid subjective bias, names of the authors, publications, year, and country were omitted during the data extraction process. Retrieved data included: (1) liver biochemical indicators: ALT (U/L), GGT (U/L), ALP (U/L) and TBIL (U/L); (2) liver fibrosis markers: HA ( $\mu$ g/L), LN ( $\mu$ g/L), IV-C ( $\mu$ g/L) and PIIIP ( $\mu$ g/L). Disagreements were resolved by discussion and consensus.

# 6. Results

# 6.1. Retrieval Results

Initially, 245 papers were retrieved by screening the title, abstract, and inclusion and exclusion criteria. Finally, 22 standard randomized controlled trials were included, with a total of 1,756 subjects, among whom 893 subjects were in the treated group, and 821 subjects were in the control group (Table 1).

Xia et al. (20)	Experi- mental Group 58	Control Group	Experimental Group	Control Group	Treatment	Indicators
Xia et al. (20)	58	57			Indicators	
			NAC (8 g/d) + basic treatment	Basic treatment (Potassium magnesium aspartate 2 g/d + promote the liver cell auxin 0.1 g/d + plasma 200 ml qod + other symptom- atic and supportive treat- ments)	30 d	TBIL
Shi et al. (21)	20	20	NAC (8 g/d) + basic treatment	Basic treatment (Vitamin K 10 mg/d + promote the liver cell auxin 20 mg/d + plasma 200 ml qod or albumin 10 g qod + ranitidine 150 mg po tid + other symptomatic and supportive treatments)	45 d	ALT, AST, TBIL
Wang et al. (19)	50	25	NAC $(8 g/d) + GSH (1.2 g/d)$	GSH (1.2 g/d)	28 d	ALT, AST, TBIL
Shohrati et al. (22)	18	20	NAC (1.2 g/d) + basic treatment	Basic treatment (lamivu- dine + pegylated interferon + adefovir)	45 d	ALT, AST, ALP, TBIL
Wu et al. (23)	72	72	NAC(8 g/d) + basic treatment	Basic treatment (Vitamin K 10 mg/d + promote the liver cell auxin 20 mg/d + plasma 200 ml qod or albumin 10 g qod + ranitidine 150 mg po tid + other symptomatic and supportive treatments)	45 d	ALT, AST, TBIL
Wang et al. (24)	42	42	UDCA $(0.5 \text{ g/d})$ + GSH $(1.2 \text{ g/d})$	Yinzhihuang (30 ml/d)	8 W	ALT, GGT, ALP, TBIL
Fabris et al. (25)	40	39	UDCA (0.6 g/d) + lactulose (100-200 g/d)	Lactulose (100 - 200 g/d)	3 W	ALT, AST, GGT, ALP, TBIL
Angulo et al. (26)	21	16	UDCA (13 - 15 mg/kg/d)	D-penicillamine (the dos- age was unclear)	24 W	AST, TBIL
Cao et al. (27)	53	47	UDCA (0.75 g/d) + Ade- methionine (1.0 g/d)	Kuhuang injection (60 ml/d)	4 W	ALT, GGT, ALP, TBIL
Qureshi et al. (28)	18	12	UDCA (0.5 g/d)	Placebo (unclear)	12 W	ALT
Ratziu et al. (29)	62	64	UDCA (0.5 g/d)	Placebo (unclear)	48 W	ALT, AST, GGT, TBIL
Tkacz et al. (12)	45	15	Silibinin (0.42 g/d)	Placebo (unclear)	45 d	ALT, AST, TBIL
Flisiak et al. (30)	15	16	Misoprostol (0.8 g/d)	Silibinin (0.21 g/d)	12 W	ALT, TBIL
Flisiak et al. (31)	25	25	Silibinin (0.21 g/d) + misoprostol (0.8 g/d)	Placebo (unclear)	24 W	ALT, AST, GGT, TBIL
Gu et al. (32)	33	32	Silibinin (0.6 g/d) + oxymatrine (0.6 g/d)	Silibinin (0.6 g/d)	12 W	ALT, TBIL
Bao et al. (33)	42	42	Silibinin (0.36 g/d) + Interferon α-16 (300 million U, q.o.d.)	Interferon α-16 (300 mil- lion U, qod.)	12 w	ALT, AST
Bao et al. (34)	86	86	Silibinin (0.36 g/d) + Lamivudine (0.1 g/d)	Lamivudine (0.1 g/d)	48 W	ALT, AST, ALP, TBIL

 Table 1. Basic Characteristics of the Included Studies <sup>a</sup>

Longl	Let al.
-------	---------

Kim et al. (35)	42	43	UDCA (0.6 g/d) + Can- desartan (0.008 g/d)	Candesartan (0.008 g/d)	24 w	ALT, AST, GGT, TBIL
Wang et al. (36)	45	44	Silibinin (0.315 g/d) + protect liver treat- ment + Lamivudine (0.1 g/d)	Protect liver treatment (energy mixture, inosine, salvia miltiorrhiza, pro- moting liver cell growth hormone and vitamin) + Lamivudine (0.1 g/d)	NA	HA, PC, CIV, LN
Wu et al. (37)	40	40	UDCA (13-15 mg/kg/d) + Fuzhenghuayu Capsules (4.5 g/d)	Fuzhenghuayu Capsules (4.5 g/d)	48 W	ALT, AST, GGT, TBIL, ALP, HA, LN, IVC, PIIIP
Mao et al. (38)	36	34	Tanshinone (0.06 g/d) + Oxymatrine (0.6 g/d)	Tanshinone (0.06 g/d)	4 W	ALT, AST, TBILI, HA, LN, PIIIP, IVC
Zhou et al. (39)	30	30	Valsartan (0.08 g/d) + Silibinin (0.14 g/d)	Silibinin (0.14 g/d)	12 W	HA, LN, IV-C, PIIIP

<sup>a</sup> Abbreviations: ALT, Alanine aminotransferase Aminotransferase; ALP; alkaline Alkaline phosphatase Phosphatase; AST, aspartate Aspartate aminotransferase Aminotransferase; CIV collagen Collagen type IV; HA, hyaluronic Hyaluronic acid Acid; LN, laminin Laminin; PIIIP, procollagen Procollagen III peptide Peptide; TBIL, total bilirubin; γ-GGT, gamma-glutamyl Glutamyl transpeptidase Transpeptidase

#### 6.2. Treatment Type

The meta-analysis groups were: 1) liver protective drug plus antiviral drug versus antiviral drug alone to assess efficacy of altering ALT, AST, ALP and TBIL levels (Table 1 ; Figure 1); 2) liver protective drug (treatment group) versus placebo to assess protective effects in terms of ALT and TBIL (Table 1 ; figures 3 and 4); 3) combination of two hepatoprotective agents versus a single agent in terms of ALT, AST, ALP, GGT, TBIL (Table 1 ; Figure 4); 4) one protective agent versus another in terms of normalization rates of ALT and TBIL (Table 1; Figure 5); 5) evaluation of the effects of a combination of two kinds of protective agents versus a single protective agent in terms of HA, LN, IV-C and PIIIP (Table 1 ; figures 6 and 7) as hepatic fibrosis markers.

# 6.3. Hepatoprotective Drug Combined With Antiviral Drug vs. Antiviral Drug Alone

Six randomized controlled trials reported on the use of a hepatoprotective drug in combination with an antiviral agent treatment of chronic hepatitis B. The test and control groups included 741 and 645 subjects, respectively. There was a statistically significant heterogeneity between the studies (I2 > 50%), and hence, a randomeffects model was used. Meta-analysis showed that using a combination of hepatoprotective and antiviral drugs was more effective than a single antiviral agent to reduce serum levels of ALT, AST, ALP and TBIL. ALT (WMD = -22.98; 95% CI (-34.98, -10.97)), AST (WMD= -26.20; 95% CI [-44.60, -7.81]), ALP (WMD = -56.19; 95% CI [-85.27, -27.11]) and TBIL (WMD= -5.58; 95% CI [-9.50, 1.66]) (Figure 1).

#### 6.4. Hepatoprotective Agents vs. Placebo

Five randomized controlled clinical trials reported the effects of three hepatoprotective agents compared with placebo on liver function indexes in patients with chronic hepatitis B, including ALT and TBIL. In these trials, the control and treatment groups included 144 and 140 subjects, respectively; since there was no significant heterogeneity between the studies (I2 < 50%), a fixed effect model was applied. Meta-analysis showed that all three hepatoprotective agents significantly decreased ALT levels in patients with hepatitis B. NAC was associated with greater efficacy compared to UDCA and silibinin. The impact of UDCA and silibinin on ALT levels in patients with hepatitis B were considerable: NAC (WMD = -25.66; P = 0.0002, 95% CI [-39.02, -12.31]), UDCA (WMD = -22.32; P = 0.03, 95% CI [-49.52, 4.72]) (Figure 2).

UDCA was superior over NAC and silibinin to reduce TBIL in patients with hepatitis B. Meta-analysis showed that NAC (WMD = -2.56; P = 95% CI [-4.95, -0.17]), UDCA (WMD = -3.48; 95% CI [-7.37, -0.31]), silibinin (WMD = -2.09; 95% CI [-8.70, 4.52]). However, the differences were not statistically significant (I2 = 0%) using a fixed-effects model (Figure 3).

# 6.5. Two Kinds of Hepatoprotective Agents vs. a Single Hepatoprotective Agent

Five randomized controlled clinical trials were employed to test the efficacy of two hepatoprotective agents compared to only one to treat patients with chronic hepatitis B. There were 618 subjects in the two hepatoprotective agents, and the single hepatoprotective agent groups, respectively. The heterogeneity between the studies was statistically significant (I2 > 50%). Using a random effects model, meta-analysis showed that the two hepatoprotective agents group was better than the single agent to reduce ALT, AST, GGT, ALP and TBIL levels in patients with hepatitis B. ALT (WMD=-31.44; 95% CI [-48.57,-14.32]), AST (WMD = -14.54; 95% CI [-29.24, 0.16]), GGT (WMD = -26.98; 95% CI [-54.66, 0.70]), ALP (WMD = -29.86; 95% CI [-52.65, -7.07]), TBIL (WMD = -4.84; 95% CI [-9.86, 0.18]) (Figure 4).

Long L et al.	
---------------	--

Study or Subgroup         Mean         SD         Total         Mean         SD         Total         Weight         IV, Pandom,           1.1.1 The reduce amounts of A LT         Bao         Weight         IV, Pandom,         1.1.1 The reduce amounts of A LT         Bao         Weight         IV, Pandom,         1.1.1 The reduce amounts of A LT         Bao         Weight         IV, Pandom,         1.1.1 The reduce amounts of A LT         Bao         Weight         IV, Pandom,         1.1.2         1.1.2         86         52%         -45.87 [59.46,         Dr. Tori Hudson 1992         31.65         8.96         45         36.89         10.73         15         8.0%         -5.24 [-11.2]         Fisiak 1997         40.56         29.34         25         79.43         57.2         25         2.5%         -38.87 [64.07,           Huma Oureshi 2006         78.31         7.62         18         87.13         6.81         12         8.2%         -8.82 [-14.04           Shi XF et al 2005         42.1         23.41         20         65.41         32.91         20         4.0%         -23.31 [-41.01           Xie J et al 2006         49.71         19.73         42         77.24         28.52         42         6.3%         -27.53 [-38.02,	-32.28] 7,0.79] -13.67] 4, 3.60] -5.61] -17.04] -10.97] • -28.76] -28.76]
Bao YF et al. 2006       38.56       29.34       86       84.43       57.2       86       5.2%       .45.87       [59.46,         Dr. Tori Hudson 1992       31.65       8.96       45       36.89       10.73       15       8.0%       .5.24       [-11.27]         Flisiak 1997       40.56       29.34       25       79.43       57.2       25       2.5%       .38.87       [64.07,         Huma Dureshi 2006       78.31       7.62       18       87.13       6.81       12       8.2%       .8.82       [-14.04         Shi XF et al 2005       42.1       23.41       20       65.41       32.91       20       4.0%       .23.31       [-41.01         Kie Jet al 2006       49.71       19.73       42       77.24       28.52       42       6.3%       .27.53       [-38.82,         Subtotal (95% CI)       236       200       34.2%       .22.98       [-34.98, -         Subtotal (95% CI)       236       200       34.2%       .22.98       [-34.98, -         Test for overal effect: Z= 3.75 (P = 0.0002)       11.2       The reduce amounts of A ST       86       6.4%       .38.93 [49.10,         Dr. Tori Hudson 1992       28.35       5.74 <t< th=""><th>7, 0.79] -1367] 4, -360] -561] -17.04] -10.97] • -28.76] -28.76] -28.76] -28.76]</th></t<>	7, 0.79] -1367] 4, -360] -561] -17.04] -10.97] • -28.76] -28.76] -28.76] -28.76]
Dr. Tori Hudson 1992 31.65 8.96 45 36.89 10.73 15 8.0% -5.24 [-11.27 Flisiak 1997 40.56 29.34 25 79.43 57.2 25 2.5% -38.87 [64.07, Huma Dureshi 2006 78.31 7.62 18 87.13 6.81 12 8.2% -8.82 [-14.04 Shi XF et al 2005 42.1 23.41 20 65.41 32.91 20 4.0% -23.31 [-41.01 Kie Jet al 2006 49.71 19.73 42 77.24 28.52 42 6.3% -27.53 [-38.02, Subtot al (95% CI) 236 200 34.2% -22.98 [-34.98, - Heterogeneity: Tau <sup>2</sup> = 178.84; Chi <sup>2</sup> = 44.03, df = 5 (P < 0.00001); I <sup>2</sup> = 89% Test for overall effect: Z = 3.75 (P = 0.0002) 1.1.2 The reduce amounts of A ST Bao YF et al. 2006 46.31 21.18 86 85.24 43.23 86 6.4% -38.93 [-49.10, Dr. Tori Hudson 1992 28.35 5.74 45 35.23 3.56 15 8.9% -6.88 [-9.34 Flisiak 1997 42.31 31.38 25 82.34 59.23 25 2.4% -40.03 [-66.30,	7, 0.79] -1367] 4, -360] -561] -17.04] -10.97] • -28.76] -28.76] -28.76] -28.76] -28.76] -28.76]
Flisiak       1997       40.56       29.34       25       79.43       57.2       25       2.5%       -38.87       [64.07,         Huma       Dureshi       2006       78.31       7.62       18       87.13       6.81       12       8.2%       -8.82       [-14.04         Shi XF       et al       2005       42.1       23.41       20       65.41       32.91       20       4.0%       -23.31       [-41.01         Xie       J et al       2006       49.71       19.73       42       77.24       28.52       42       6.3%       -27.53       [-38.02,         Subtotal       (95% Cl)       236       200       34.2%       -22.98       [-34.98, -         Heterogeneity:       Tau² = 178.84; Chi² = 44.03, df = 5 (P < 0.00001); l² = 89%	-1367] 4, 360] 1, 561] -17.04] -10.97] -28.76] 4, 4.42]
Huma Dureshi 2006 78.31 7.62 18 87.13 6.81 12 8.2% 8.82 [-14.04 Shi XF et al 2005 42.1 23.41 20 65.41 32.91 20 4.0% -23.31 [-41.01 Xie Jet al 2006 49.71 19.73 42 77.24 28.52 42 6.3% -27.53 [-38.02, Subtot al (95% CI) 236 200 34.2% -22.98 [-34.98, Heterogeneity: Tau <sup>2</sup> = 178.84; Chi <sup>2</sup> = 44.03, df = 5 (P < 0.00001); I <sup>2</sup> = 89% Test for overall effect: Z = 3.75 (P = 0.0002) 1.1.2 The reduce amounts of A ST Bao YF et al. 2006 46.31 21.18 86 85.24 43.23 86 6.4% -38.93 [-49.10, Dr. Tori Hudson 1992 28.35 5.74 45 35.23 3.56 15 8.9% -6.88 [-9.34 Fisiak 1997 42.31 31.38 25 82.34 59.23 25 2.4% -40.03 [-66.30,	4, 360] 1, 561] -17.04] -10.97] -28.76] 4, 4.42]
Shi XF et al 2005       42.1       23.41       20       65.41       32.91       20       4.0%       -23.31       [-41.01         Xie J et al 2006       49.71       19.73       42       77.24       28.52       42       6.3%       -27.53       [-38.02,         Subtotal (95% CI)       236       200       34.2%       -22.98       [-34.98, -         Heterogeneity: Tau²=       178.84; Chi²= 44.03, df= 5 (P < 0.00001); l²= 89%	-17.04] -17.04] -10.97] -28.76] 
Xie Jetal 2006 49.71 19.73 42 77.24 28.52 42 6.3% 27.53 [38.02, Subtotal (95% CI) 236 200 34.2% -22.98 [-34.98, - Heterogeneity. Tau <sup>2</sup> = 178.84; Chi <sup>2</sup> = 44.03, df = 5 (P < 0.00001); I <sup>2</sup> = 89% Test for overall effect: Z = 3.75 (P = 0.0002) 1.1.2 The reduce amounts of A ST Bao YF et al. 2006 46.31 21.18 86 85.24 43.23 86 6.4% -38.93 [-49.10, Dr. Tori Hudson 1992 28.35 5.74 45 35.23 3.56 15 8.9% -6.88 [-9.34 Fisiak 1997 42.31 31.38 25 82.34 59.23 25 2.4% -40.03 [-66.30,	-17.04] -10.97] -28.76] 4. 4.42]
Subtotal (95% CI) 236 200 34.2% -22.98 [-34.98, - Heterogeneity: Tau <sup>2</sup> = 178.84; Chi <sup>2</sup> = 44.03, df = 5 (P < 0.00001); I <sup>2</sup> = 89% Test for overall effect: Z = 3.75 (P = 0.0002) 1.1.2 The reduce amounts of A ST Bao YF et al. 2006 46.31 21.18 86 85.24 43.23 86 6.4% -38.93 [-49.10, Dr. Tori Hudson 1992 28.35 5.74 45 35.23 3.56 15 8.9% -6.88 [-9.34 Fisiak 1997 42.31 31.38 25 82.34 59.23 25 2.4% -40.03 [-66.30,	-10.97] • -28.76] • 44.42] •
Heterogeneity. Tau <sup>2</sup> = 178.84; Chi <sup>2</sup> = 44.03, df = 5 (P < 0.00001); l <sup>2</sup> = 89% Test for overall effect: Z = 3.75 (P = 0.0002) 1.1.2 The recluce amounts of A ST Bao YF et al. 2006 46.31 21.18 86 85.24 43.23 86 6.4% -38.93 [49.10, Dr. Tori Hudson 1992 28.35 5.74 45 35.23 3.56 15 8.9% -6.88 [9.34 Fisiak 1997 42.31 31.38 25 82.34 59.23 25 2.4% -40.03 [66.30,	-28.76]
Test for overall effect: Z= 3.75 (P=0.0002) 1.1.2 The reduce amounts of AIST Bao YF et al. 2006 46.31 21.18 86 85.24 43.23 86 6.4% -38.93 [49.10, Dr. Tori Hudson 1992 28.35 5.74 45 35.23 3.56 15 8.9% -6.88 [9.34 Filsiak 1997 42.31 31.38 25 82.34 59.23 25 2.4% -40.03 [66.30,	4, -4.42]
1.1.2 The reduce amounts of A ST Bao YF et al. 2006 46.31 21.18 86 85.24 43.23 86 6.4% -38.93 [49.10, Dr. Tori Hudson 1992 28.35 5.74 45 35.23 3.56 15 8.9% -6.88 [9.34 Filsiak 1997 42.31 31.38 25 82.34 59.23 25 2.4% -40.03 [66.30,	4,-4.42]
Bao YF et al. 2006 46.31 21.18 86 85.24 43.23 86 6.4% -38.93 [49.10, Dr. Tori Hudson 1992 28.35 5.74 45 35.23 3.56 15 8.9% -6.88 [9.34 Filsiak 1997 42.31 31.38 25 82.34 59.23 25 2.4% -40.03 [66.30,	4,-4.42]
Dr. Tori Hudson 1992 28.35 5.74 45 35.23 3.56 15 8.9% -6.88 [9.34 Flisiak 1997 42.31 31.38 25 82.34 59.23 25 2.4% -40.03 [66.30,	4,-4.42]
Dr. Tori Hudson 1992 28.35 5.74 45 35.23 3.56 15 8.9% -6.88 [9.34 Flisiak 1997 42.31 31.38 25 82.34 59.23 25 2.4% -40.03 [66.30,	4,-4.42]
Flisiak 1997 42.31 31.38 25 82.34 59.23 25 2.4% 40.03 [66.30,	- 1993.199 - 170 -
ShiXF etal 2005 68.91 43.61 20 92.31 66.14 20 1.5% -23.40 [-58.12,	, 11.32]
Xie Jetal 2006 40.8 27.1 42 66.7 35.4 42 5.2% -25.90 [39.38,	-12.42]
Subtotal (95% Cl) 218 188 24.5% 26.20 [-44.60	
1.1.3 The ruduce amounts of ALP	
Bao YF et al. 2006 146.69 46.69 86 215.67 49.93 86 4.9% -68.98 [83.43,	-5453]
Flsiak 1997 185.69 46.69 25 224.67 49.96 25 2.3% -38.98 [65.78,	-12.18]
Subtotal (95% Cl) 111 111 7.3% -56.19 [-85.27, -	-27.11]
Heterogeneity: Tau² = 329.31; Chi² = 3.73, df = 1 (P = 0.05), l² = 73%	
Test for overall effect: Z= 3.79 (P = 0.0002)	
1.1.4 The reduce amounts of TBIL	
Bao YF et al. 2006 9.82 15.21 86 18.92 12.57 86 8.5% -9.10 [-13.27	7,-493]
Dr. Tori Hudson 1992 14.35 3.16 45 14.51 3.94 15 9.0% -0.16 [2.3	6,204]†
Flisiak 1997 10.96 16.12 25 22.32 10.57 25 7.4% -11.36 (-18.92	2,-380] —
ShiXFetal 2005 12.83 1.08 20 18.14 1.94 20 9.1% -5.31 [6.28	
Subtotal (95% CI) 176 146 34.0% -5.58 [9.50	•, -1.66]
Heterogeneity: Tau²= 12.27; Chi²= 25.15, df = 3 (P < 0.0001); P = 88%	
Test for overall effect: Z= 2.79 (P = 0.005)	
Total (95% CI) 741 645 100.0% -19.40 [-24.13,-	-14.67]
Heterogeneity: Tau²=63,72; Chi²= 229,09, df= 16 (P < 0.00001); l²=93%	-100 -50 0 50 100
Test for overall effect: Z= 8.04(P < 0.00001)	
Test for subaroup differences : ChP = 21.59. df = 3 (P < 0.0001). I <sup>2</sup> = 86.1 %	Favours (experimental) Favours (control)

In patients with chronic hepatitis B infection treated with combination hepatoprotective and antiviral drug vs. antiviral drug alone. Data are presented as pooled mean difference using a random-effects model and 95% confidence intervals.

Long L	et al.
--------	--------

	Exp	eriment	al	(	Control			Mean Difference		Mean Di	fference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% (		IV, Fixe	d, 95% Cl	
2.1.1 The reduce amo	ounts of	ALT (N	AC)									
Guo SH et al. 2005	51	22.3	18	70.5	60.6	20	11.6%	-19.50 [47.99, 8.99]				
Shohrati et al. 2010 Subtotal (95% CI)	47	26.4	72 90	74.4	59.9	72 92		-27.40 [-42.52, -12.28] -25.66 [-39.02, -12.31]		•		
Heterogeneity: Chi²=	0.23, df=	= 1 (P =	0.63);	²= 0%								
Test for overall effect:		· · · · · · · ·										
2.1.2 The reduce amo	ounts of	ALT (U	IDCA)									
Albert JC et al. 1999	57.13	19.22	21	79.45	37.11	16	23.6%	-22.32 [-42.28, -2.36]		-		
Subtotal (95% CI)			21			16	23.6%	-22,32 [-42,28,-2,36]		-		
Heterogeneity: Not ap	plicable											
Test for overall effect:	Z= 2.19	(P = 0)	03)									
2.1.3 The reduce amo	ounts of	ALT (s	ilibinin	1)								
GU X B et al. 2012	57.13	19.22	21	79.45	37.11	16	23.6%	-22.32 [-42.28, -2.36]		-		
Subtotal (95% CI)			21			16	23.6%	-22.32 [-42.28, -2.36]		-		
Heterogeneity: Not ap	plicable											
Test for overall effect:	Z= 2.19	(P = 0)	03)									
Total (95% CI)			132			124	100.0%	-24.08 [-33.78, -14.38]		•	-94	
Heterogeneity: Chi²=	0.34, df=	= 3 (P =	0.95);	²= 0%					-100	-50	1 I 0 50	100
Test for overall effect:	Z= 4.87	(P < 0)	00001)							Contract and the	Favours (com	
Test for subaroup diffe	erences:	Chi <sup>2</sup> = 0	.11.df	= 2 (P =	0.94).	P=0%			rawus	spennendij	rawus pon	uvij

In patients with chronic hepatitis B infection treated with hepatoprotective drugs vs. placebo. Data are presented as pooled mean difference using a random-effect model and 95 % confidence intervals.

6.6. Effects of two Versus one Hepatoprotective Agent on Recovery of Liver Function in Patients With Hepatitis B

Figure 2. Meta-Analysis Forest Plots Indicating Reduced Amounts of ALT

Three randomized controlled clinical trials reported the effects of combining two hepatoprotective drugs compared to a single agent on the recovery rate of liver indicators in patients with hepatitis B; 173 subjects who used a combination of two agents were compared to 123 subjects who used only one agent. The heterogeneity between the studies was statistically significant (I2 = 0%, P = 0.98). Therefore, a fixed-effects model was used. Compared with the single agent group, meta-analysis showed that using a combination of two hepatoprotective drugs was more effective than only one in restoring liver indicators to normal levels (two hepatoprotective agents group vs. single hepatoprotective agent group = 75.2% vs. 49.5%). ALT (72.3% vs. 48.7%, RR = 1.44, 95% CI [1.01, 2.04]), TBIL (77.8% vs. 50%, RR = 1.53, 95% CI [1.21, 1.95]). The recovery rate of the group that used two hepatoprotective agents was 25.7% higher than the one treated by a single agent, (RR = 1.50, P < 0.0001, 95% CI [1.23, 1.83]) (Figure 5).




Figure 3. Meta-Analysis Forest Plots Describing the Effects of Hepatoprotective Agents vs. Placebo on TBIL Levels

In patients with chronic hepatitis B infection. Data are presented as pooled relative risks using a fixed-effect model and 95% confidence intervals.

# 6.7. Effects of Hepatoprotective Agents on Liver Fibrosis Indexes in Patients With Hepatitis B

Three randomized controlled clinical trials reported the effects of hepatoprotective agents on liver fibrosis markers, HA, IV-C and PIIIP. From the three studies, the test and control groups consisted of 121 and 118 subjects, respectively. The heterogeneity between the studies was statistically significant (I2 > 50%). Thus, a random-effects model was used. The results indicated that hepatoprotective agents were indeed associated with improved indices of hepatic fibrosis compared to placebo: HA (WMD = -55.65, 95% CI [-75.00, -36.31]), IV-C (WMD = -29.23, 95% CI [-41.21, -17.25]), PIIIP (WMD = -53.79, 95% CI [-69.03, -38.55]) (Figure 6).

Four randomized controlled clinical trials reported the effects of combined hepatoprotective agents versus a single agent on the liver fibrosis index, LN. The group Figure 4. Meta-Analysis Forest Plots for Effects

	Exp	erimen	tal	(	Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% CI
4.1.1 The reduce amo	unts of	ALT							
Cao R et al 2013	50	39	53	77	34	47	5.5%	-27.00 [41.31, -12.69]	
Wang Net al. 2008	34.54	28.78	50	88.17	59.42	25	3.0%	-53.63 [78.25, -29.01]	
Wang X Y et al. 2008	36.3	72	42	50.7	4.8	42	9.3%	-14.40 [17.02, -11.78]	Y
Yang X Y 1999	41.95	24.3	15	82.78	24.55	16	4.6%	-40.83 [58.03, -23.63]	
Subtotal (95% CI)			160			130	22.4%	-31.44 [-48.57, -14.32]	•
Heterogeneity: Tau² = :	242.49;	Chi² = 2	0.66,0	f= 3 (P	= 0.000	1); F =	85%		
Test for overall e flect : 2	Z=3.60	(P = 0)	0003)						
4.1.2 The reduce amo	unts of	AST							
Wang Net al. 2008	34.54	2124	50	49.08	34.36	25	5.3%	-14.54 [29.24, 0.16]	
Subtotal (95% CI)			50			25	5.3%	-14.54 [-29.24, 0.16]	•
Heterogeneity: Not app	licable								
Test for overall e ffect : 2	Z=1.94	(P = 0)	05)						
4.1.3 The reduce amo									10.22 - 11
Cao R et al 2013	45							-42.00 [56 21, -27.79]	CO
Wang XY et al. 2008	15.9	5.9		29.6	10.5	42		-13.70 [17.34, -10.06]	
Subtotal (95% CI)			95					-26.98 [-54.66, 0.70]	
Heterogeneity: Tau² = 3				f= 1 (P	= 0.000	2); F =	93%		
Test for overall e ffect : 2	Z= 1.91	(P = 0)	D6)						
4 4 <b>The set does and</b>									
4.1.4 The reduce amo				1.00			0.74		10 million 100
Cao R et al 2013	102							-44.00 [64.86, -23.14]	
Wang XY et al. 2008	16.9	7.6	42 95	37.2	12.1	42 89		-20.30 [24.62, -15.98] -29.86 [-52.65, -7.07]	-
Subtotal (95% CI) Ustomaanaëus Tau? - 1	004.00-	06:2 - 4		- 1/0 -	0.003			-29 26 [-52 25, 1 21]	
Heterogeneity: Tau² = : Test for overall e flect : :				- 1(P -	003),	r-791	b		
TEST DI OVEIAILE ILEU. A	2-201	(P - 0)	) )						
4.1.5 The reduce amo	unts of	TBIL							
Cao R et al 2013	6.7	4.8	53	14.7	11	47	9.2%	-8.00 [11.40, -4.60]	
Wang Net al. 2008	9.32			13.16		25		-3.84 [-8.42, 0.74]	-
Wang XY et al. 2008	15.9				7.8	42		-1.30 [-4.31, 1.71]	•
Xia G et al. 2009	6.78					57	9.4%	-1.34 [-3.46, 0.78]	
Yang X Y 1999	22.47			30.69		16	8.2%	-822 [15.04, -1.40]	-
Subtotal (95% CI)	22.41	0.12	218	00.03		187	45.0%	-4.02 [-7.02, -1.02]	
									10.5

In patients with chronic hepatitis B infection treated with the combination of two liver protective drugs vs. one liver protective drug. Data are presented as pooled mean difference using a random-effect model, and 95% confidence intervals.

representing the combined hepatoprotective agents included 151 subjects, whereas the single hepatoprotective agent group had 148 subjects. There was no significant heterogeneity (I2 < 50%); therefore, a fixed-effects model was used. Meta-analysis showed that the two hepatoprotective agents was superior to the single one in terms of reducing LN levels (WMD = -33.91, 95% CI [-40.51, -27.31]) (Figure 7).

#### 6.8. Assessment of Publication Bias

A Funnel plot analysis of bias among 12 trials on the effects of hepatoprotective agents on normalization of ALT, AST and TBIL was conducted, in patients with hepatitis B (Figure 8). The Funnel plot showed that the distribution of the samples were asymmetrical, suggesting that some of the test methodologies may have been of low quality, and publication bias may have been present.

Figure 5. Meta-Analysis Forest Plots Indicating the Normalization Rates of ALT and TBIL Odds Ratio Experimental Control **Odds Ratio** M-H. Fixed, 95% Cl Study or Subgroup Events Total Events Total Weight M-H. Fixed, 95% Cl 5.1.1 The normalization rate of ALT Wang N et al. 2008 38 50 13 25 24.0% 2.92 [1.06, 8.09] Yang X Y 1999 15 7 16 15.6% 1.93 [0.46, 8.05] 9 2.53 [1.10, 5.80] 65 Subtotal (95% CI) 41 39.6% 47 Total events 20 Heterogeneity: Chi2= 0.22, df = 1 (P = 0.64); I2= 0% Test for overall effect: Z = 2.19 (P = 0.03) 5.1.2 The normalization rate of TBIL 3.59 [1.60, 8.03] Wang N et al. 2008 45 58 28 57 36.5% 2.92 [1.06, 8.09] Xia Get al. 2009 38 50 25 24.0% 13 82 3.32 [1.77, 6.25] Subtotal (95% CI) 10860.4% Total events 83 41 Heterogeneity: Chi2= 0.09, df = 1 (P = 0.76); I2= 0% Test for overall effect: Z = 3.73 (P = 0.0002) 173 Total (95% CI) 123 100.0% 3.01 [1.82, 4.97] 61 Total events 130 Heterogeneity: Chi2 = 0.56, df = 3 (P = 0.91); I2 = 0% 0.1 0.01 10 100 Test for overall effect: Z = 4.31 (P < 0.0001) Favours [experimental] Favours [control] Test for subgroup differences:  $Chi^2 = 0.26$ , df = 1 (P = 0.61), P = 0%.

In patients with chronic hepatitis B infection treated with two vs. one hepatoprotective agent. Data are presented as pooled relative risks, adopted fixedeffect model and 95 % confidence intervals, by trial.

	Exp	erimenta	al	C	ontrol			Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	IV, Random, 95% CI		
6.1.1 The reduce amo	unts of H	łA									
Mao ZY et al. 2014	882	37.5	36	139.1	46.5	34	10.4%	-50.90 [70.76, -31.04]			
Wu Y et al. 2012	106.5	20.2	40	176.2	21.1	40	13.0%	-69.70 [78.75, -60.65]	-		
Zhang XX et al. 2012	178.95	52.62	45	216.32	74.03	44	8.6%	-37.37 [64.11, -10.63]			
Subtotal (95% CI)			121			118	32.0%	-55.65 [75.00, -36.31]	•		
Heterogeneity: Tau <sup>2</sup> = 2	203.90; C	hi² = 7.0	1,df=	2 (P = 0	03); l²=	71%					
Test for overall effect: 2	Z=5.64(	P < 0.00	001)								
6.1.2 The reduce amo	unts of M	V-C									
Mao ZY et al. 2014	45.6	26.3	36	69.3	37.2	34	11.6%	-23.70 [38.87, -8.53]	The second		
Wu Y et al. 2012	132.8	16.5	40	171.2	22.6	40	13.1%	-38.40 [47.07, -29.73]	-		
Zhang XX et al. 2012	148.45	35.98	45	169.45	40.36	44	11.4%	-21.00 [36.90, -5.10]			
Subtotal (95% CI)			121			118	36.2%	-29.23 [41.21, -17.25]	•		
Heterogeneity: Tau <sup>2</sup> = 6	57.78; Ch	i² = 5.08	, df = 2	(P = 0.0	8);  ²=	61%					
Test for overall effect: 2	2=4.78 (	P < 0.00	001)	0.000	55						
6.1.3 The reduce amo	unts of P	œ									
Mao ZY et al. 2014	782	43.6	36	128.9	55.3	34	9.5%	-50.70 [74.12, -27.28]			
Wu Y et al. 2012	122.1	16	40	185	22.6	40	13.1%	-62.90 [71.48, -54.32]			
Zhang XX et al. 2012	170.8	49.52	45	208.37	66	44	9.2%	-37.57 [61.85, -13.29]			
Subtotal (95% CI)			121			118	31.8%	-53.79 [69.03, -38.55]	•		
Heterogeneity: Tau <sup>2</sup> = 9	9.17; Ch	<sup>2</sup> = 427	, df = 2	(P=0.1	2);  2= :	53%					
Test for overall effect: 2	Z=6.92(	P < 0.00	001)								
Total (95% CI)			363			354	100.0%	-4428 [57.01, -31.55]	. 🔶		
Heterogeneity: Tau <sup>2</sup> = 3	302.96; C	hi² = 59.	95, df	= 8 (P < 1	0.00001	);  ²= 8	7%		-100 -50 0 50 1		
Test for overall effect: 2	2=6.82(	P < 0.00	001)						-100 -50 0 50 1 Favours (experimental) Favours (control)		


Figure 6. Meta-Analysis With Forest Plots Effects of two Hepatoprotective Agents vs. a Single Hepatoprotective Agent on Levels of HA, IV-C and PIIIP


In patients with liver fibrosis. Data are presented as pooled mean difference using a random-effects model and 95 % confidence intervals, by trials.

Figure 7. Meta-Analysis Forest Plots of LN Levels in Patients With Liver Fibrosis Infection Treated with Two vs. one Hepatoprotective Agents

	expe	riment	al	с	ontrol			Mean Difference		Mean D	ifference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% (	1	IV, Fixe	d, 95% Cl	
Mao ZY et al. 2014	66.8	37.4	36	91.4	512	34	11.7%	-24.60 [-45.71, -3.49]		-		
Wu Y et al . 2012	128	16.3	40	163.5	212	40	75.6%	-35.50 [43.79, -27.21]		2.0		
Zhang XX- et al. 2012	171.87	39.25	45	198.73	56.14	44	12.8%	-26,86 [-47,03, -6,69]		-		
Total (95% CI)			121			118	100.0%	-33.13 [-40.33, -25.92]		٠		
Heterogeneity: Chi²= 1.	31, df = 2	(P=05	(2);  ²=	0%					.100	-50	1 1 0 50	100
Test for overall effect: Z	= 9.01 (P	< 0.000	101)							-ou [experimental]	i	

Data are presented as pooled mean difference using a random-effects model, and 95% confidence intervals.





#### 7. Discussion

The current model is expected to maximize long-term treatment of severe liver disease caused by HBV infection to suppress the virus, improve inflammation and necrosis, and deliver adjuvant therapy to manage complications.

The results of the current study showed that after a certain treatment course of a combined hepatoprotective and antiviral drugs, liver function and fibrosis index decreased in most of the subjects. Combination therapy was more effective than a single hepatoprotective agent to reduce liver cell damage, promote the liver cell membrane and promote the recovery of liver function, and it may delay the formation and development of hepatic fibrosis (38). Some studies showed a synergistic effect between hepatoprotective agents and antiviral drugs. It may be related to the improvement in drug tolerance due to hepatoprotective agents in patients with

hepatitis B (34, 40). In 2006, Qureshi et al reported that large doses of ursodeoxycholic acid reduces ALT levels in patients with hepatitis B (28). The meta-analysis of the current study showed that acetylcysteine, ursodeoxycholic acid and silibinin significantly reduced ALT, and were a liver function marker in patients with hepatitis B. The reduction in ALT levels by acetylcysteine was better than ursodeoxycholic acid and silibinin. This may be related to the ability of acetylcysteine to inhibit the expression of serum II-18, IFN- $\gamma$  and NO in the patients with hepatitis B. Some studies stated that acetylcysteine should be used, and that it was more beneficial in early stages of liver disease (21).

The limitations of the study included the retrospective nature, variability of the quantity, quality and sources of the hepatoprotective agents, and the variability, and effectiveness of the antiviral agents. High-quality multicenter, large sample, randomized, double-blind and controlled clinical trials are necessary to confirm the current observations.

#### Acknowledgements

The current work was supported by the social development research project of Shaanxi science and technology agency (No. 2012k14-04-01) and the project of Xi'an medical college (No. XYFY11-02).

#### **Authors' Contributions**

Authors had equal contribution.

# Funding/Support

The current research was financially supported by Shaanxi Science and Technology Agency (No. 2012k14-04-01); the project of Xi'an Medical College affiliated hospital (No. XYFY11-02).

#### References

- Liang GN, Chen LH. Glycyrrhizin injection combined with Danshen injection observe the effect of hepatitis B liver fibrosis. J Tibetan Med. 2010;31(1):24–5.
- Alavian SM, Tabatabaei SV, Ghadimi T, Beedrapour F, Kafi-Abad SA, Gharehbaghian A, et al. Seroprevalence of Hepatitis B Virus Infection and Its Risk Factors in the West of Iran: A Population-based Study. Int J Prev Med. 2012;3(11):770–5.
- 3. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209-18.
- Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655–69.
- Kim BK, Kim do Y, Park JY, Ahn SH, Chon CY, Kim JK, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. *Liver Int*. 2010;30(4):546–53.
- Lim YS, Kim WR. The global impact of hepatic fibrosis and endstage liver disease. *Clin Liver Dis.* 2008;12(4):733–46.
- Cao R, Hu XD, Cheng H. Observation on the clinical efficiency of adenosine combine with ursodeoxycholic acid in the treatment of chronic hepatitis B with severe jaundice. *Chin Hosp Pharm J Dis.* 2003;**32**(6):481-3.
- Gao Y, Song MZ, Liang CR. Clinical Observation of Ademetionine Combined With Ursodeoxycholic Acid in the Treatment of Chronic Severe Cholestatic Hepatitis. *Chin Hosp Pharm Dis.* 2013;14(3):68–9.
- Joo SS, Kang HC, Won TJ, Lee DI. Ursodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1 beta and nitric oxide in rat microglia. Arch Pharm Res. 2003;26(12):1067–73.
- Fekaj E, Gjata A, Maxhuni M. The effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment: a prospective, randomized, and controlled study. *BMC Surg.* 2013;13:38.
- Boberg KM, Wisloff T, Kjollesdal KS, Stovring H, Kristiansen IS. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. *Aliment Pharmacol Ther.* 2013;38(7):794–803.
- Tkacz B, Dworniak D. [Sylimarol in the treatment of acute viral hepatitis]. Wiad Lek. 1983;36(8):613–6.
- 13. Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, et al. Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. *Eur J Clin Microbiol Infect Dis.* 2013;**32**(5):657-69.
- 14. Ren BR, Zhao YY, Xu BH, Wu JL, Chen J, Liang CY. Research of silymarin extraction and silibinin purification. *Lishizhen Med Materia Med Res.* 2012;**23**(3):655–6.

- Feher J, Lengyel G. [Silymarin in the treatment of chronic liver diseases: past and future]. Orv Hetil. 2008;149(51):2413–8.
- Hoffer E, Baum Y, Tabak A, Taitelman U. N-acetylcysteine increases the glutathione content and protects rat alveolar type II cells against paraquat-induced cytotoxicity. *Toxicol Letters*. 1996;84(1):7-12.
- Harrison P, Wendon J, Williams R. Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure. *Hepatology*. 1996;23(5):1067–72.
- McClain CJ, Price S, Barve S, Devalarja R, Shedlofsky S. Acetaminophen hepatotoxicity: An update. *Curr Gastroenterol Rep.* 1999;1(1):42–9.
- Wang N, Shi XF, Guo SH, Zhang DZ, Ren H. [A clinical study of Nacetylcysteine treatment in chronic hepatitis B patients]. *Zhonghua Gan Zang Bing Za Zhi*. 2008;16(7):487–9.
- Xia G. The clinical efficacy observation of acetylcysteine injection on 58 cases of chronic severe hepatitis B. West Chin Med J. 2009;24(5):1239–40.
- 21. Shi XF, Guo SH, Wu G, Wang ZY, Ren H, Liu Q. The clinical curative effect observation of acetylcysteine injection on 40 cases of chronic hepatitis B. *J Chongqing Med Univ.* 2005;**30**(1):115–21.
- Shohrati M, Dermanaki F, Babaei F, Alavian SM. Evaluation of the effects of oral N-acetylcysteine and a placebo in paraclinical and oxidative stress parameters of patients with chronic hepatitis B. *Hepat Mon.* 2010;10(2):95–100.
- Wu G, Guo SH. The Clinic Study of N-Acetylcysteine Injection Therapy to Chronic Hepatitis B. *Chongqing Med Univer*. 2004;3:25-49.
- Wang X, Shen S, Li N, Li Y. [Effect of Ursodeoxycholi acid on liver cirrhosis with hepatitis B]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35(2):171-5.
- Fabris P, Tositti G, Mazzella G, Zanetti AR, Nicolin R, Pellizzer G, et al. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. *Aliment Pharmacol Ther*. 1999;**13**(9):1187–93.
- Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. *Hepatology*. 1999;29(3):644–7.
- CAO R, Hu XD, CHENG H, HUANG S, BAI T, GAN H, et al. Observation on the clinical efficiency of adenosine methionine combined with ursodeoxycholic acid in the treatment of chronic hepatitis B with severe jaundice. *Chinese J Hos Pharm*. 2013;6:019.

- Qureshi H, Mehdi I, Ahmed WU, Alam SE. Role of ursodeoxycholic acid in lowering ALT in chronic liver disease. J Pak Med Assoc. 2006;56(3):130–1.
- Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. *J Hepatol.* 2011;54(5):1011–9.
- Flisiak R, Prokopowicz D. Effect of misoprostol on serum beta2microglobulin in the course of viral hepatitis B. Eur J Gastroenterol Hepatol. 1999;11(11):1227–30.
- Flisiak R, Prokopowicz D. Effect of misoprostol on the course of viral hepatitis B. *Hepatogastroenterology*. 1997;44(17):1419–25.
- Gu XB, Yang XJ, Hua Z, Lu ZH, Zhang B, Zhu YF, et al. Effect of oxymatrine on specific cytotoxic T lymphocyte surface programmed death receptor-1 expression in patients with chronic hepatitis B. *Chin Med J (Engl).* 2012;**125**(8):1434–8.
- Bao FY, Xie J. Silybin phospholipid complex combinated with interferon treating hepatitis B. J Cent Plains Med. 2006;33(15):70–1.
- 34. Bao FY, Qiu PY. Analyzing the adjunctive therapy of silibinin phospholipid complex treat chronic hepatitis B in 86 cases. *Shandong Med.* 2006;**26**:26–31.
- Kim MY, Cho MY, Baik SK, Jeong PH, Suk KT, Jang YO, et al. Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study. *Liver Int.* 2012;**32**(6):977–87.
- Wang H, Zhao YL, Xu KC. [Clinical and pathological study on effects of Qianggan Capsule combined lamivudine on hepatic fibrosis in patients with chronic hepatitis B]. *Zhongguo Zhong Xi Yi Jie He Za Zhi*. 2006;26(11):978–80.
- 37. Wu Y, Yao DK, Zhu L. [Clinical observation on the safety and efficacy of ursodeoxycholic acid and fuzheng huayu capsule in the treatment of primary biliary cirrhosis]. *Zhongguo Zhong Xi Yi Jie He Za Zhi.* 2012;**32**(11):1477–82.
- Mao ZY, Xiao M, Wu XJ, Tao LG. TanIIA, Oxymatrine combined therapy on liver function in patients with chronic hepatitis B and liver fibrosis. *Pract Clin Med.* 2014;15(2):21–3.
- Zhou XY, Gao C, Gao XC, Liu XL, Li LH, Wang X. Clinical effects of valsartan on liver fibrosis indexes in patients with alcoholic liver cirrhosis. *Chin J Integr Trad Western Med Live Dis.* 2014;24(2):85–6.
- 40. Gou W, Wang YL. To observe the effect of interferon α-2b combined with silymarin to treat chronic hepatitis B. *Clin Hepatol*. 2004;**5**:302.